Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioterrorism -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (271)	10/17/2001 9:54:44 AM
From: scaram(o)uche	Respond to of 891

Dear Subscriber, For reasons that are not clear our server decided to send out an incorrect message suggesting people had been deleted from the list, this is not the case. It may be indirectly related to our attempts to set up a new Bioterrorism newsfeed. If you wish to subscribe to this NEW newsfeed please go to the following account biologistsonline.com

To: nigel bates who wrote (271)	10/17/2001 1:31:21 PM
From: Jibacoa	Respond to of 891

Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen has been previously reported: ncbi.nlm.nih.gov elsevier.com VICL has among its products DNA Vaccines for Infectious Diseases: (I don't know if they had done any work on anthrax) "Through its collaborations with major pharmaceutical companies, the Company has seen its naked DNA vaccine technology advance in recent years into human testing with developmental vaccines. Clinical programs in 2000 based on its licensed technology included a Phase I trial of a DNA vaccine to prevent infection with HIV, a Phase I trial of a DNA vaccine to treat patients already infected with HIV, and a Phase II trial of a DNA vaccine to prevent infection with malaria. Because of the large-scale development programs, manufacturing capacity and distribution channels required to successfully market a vaccine, the Company believes collaborations with major pharmaceutical companies are the most effective way to apply its patented technology in the emerging DNA vaccine field. The Company has long-standing, active partnerships with Merck and Aventis Pasteur." Bernard